Prognostic Value of Plasma hPG₈₀ (Circulating Progastrin) in Metastatic Renal Cell Carcinoma.

ABSTRACT: Precise management of kidney cancer requires the identification of prognostic factors. hPG₈₀ (circulating progastrin) is a tumor promoting peptide present in the blood of patients with various cancers, including renal cell carcinoma (RCC). In this study, we evaluated the prognostic value of plasma hPG₈₀ in 143 prospectively collected patients with metastatic RCC (mRCC). The prognostic impact of hPG₈₀ levels on overall survival (OS) in mRCC patients after controlling for hPG₈₀ levels in non-cancer age matched controls was determined and compared to the International Metastatic Database Consortium (IMDC) risk model (good, intermediate, poor). ROC curves were used to evaluate the diagnostic accuracy of hPG₈₀ using the area under the curve

SUBMITTER: Kohli M 

PROVIDER: S-EPMC7864155 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature